Table 1

Baseline patient characteristics

30 mg/m2 (N = 4)40 mg/m2 (N = 6)50 mg/m2 (N = 6)Original 50 mg/m2 (N = 2)Phase 2 (50 mg/m2) (N = 9)Total (N = 27)
Age
 Median (range)70.0 (57.0-76.0)62.5 (49.0-69.0)61.5 (59.0-75.0)72.5 (70.0-75.0)70.0 (57.0-76.0)66.0 (49.0-81.0)
Gender
 Female1 (25.0%)4 (66.7%)3 (50.0%)0 (0.0%)1 (25.0%)13 (48.1%)
 Male3 (75.0%)2 (33.3%)3 (50.0%)2 (100.0%)3 (75.0%)14 (51.9%)
Months from diagnosis to registration
 Median (range)31.9 (20.9-47.1)43.8 (10.1-67.9)66.7 (6.7-134.3)113.6 (20.1-207.1)31.9 (20.9-47.1)41.6 (6.7-207.1)
International staging
 Stage 10 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (11.1%)1 (3.7%)
 Stage 23 (75.0%)2 (33.3%)3 (50.0%)1 (50.0%)2 (22.2%)11 (40.7%)
 Stage 31 (25.0%)4 (66.7%)3 (50.0%)1 (50.0%)6 (66.7%)15 (55.6%)
Prior exposure
 Lenalidomide2 (50.0%)6 (100.0%)4 (66.7%)1 (50.0%)6 (66.7%)19 (70.4%)
 Bortezomib3 (75.0%)5 (83.3%)6 (100.0%)2 (100.0%)8 (88.9%)24 (88.9%)
Metaphase cytogenetics
 Normal2 (50.0%)2 (33.3%)2 (33.3%)1 (50.0%)3 (33.3%)10 (37.0%)
 Abnormal2 (50.0%)3 (50.0%)4 (66.7%)1 (50.0%)5 (55.6%)15 (55.6%)
 Not done0 (0.0%)1 (16.7%)0 (0.0%)0 (0.0%)1 (11.1%)2 (7.4%)
FISH result
 13q-222039
 17p-111025
 t(11;14)221016
 t(4;14)101002
 t(14;16)000112